APO Research
Talk to an analyst

APO RESEARCH · REPORT

HIV Therapy Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global HIV Therapy Drug Market Outlook and Growth Opportunities 2026

30 December 2025215 pages

Choose your research edition.

Industry ResearchHIV Therapy Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV Therapy Drug Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal HIV Therapy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV Therapy Drug Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV Therapy Drug Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global HIV Therapy Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for HIV Therapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HIV Therapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV Therapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the HIV Therapy Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the HIV Therapy Drug market include AbbVie Inc., Affine Formulations Limited, Beacon Pharmaceuticals, Biocon Limited, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cipla, Frontier Biotechnologies and Genentech, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global HIV Therapy Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HIV Therapy Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HIV Therapy Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the HIV Therapy Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

HIV Therapy Drug Segment by Company

AbbVie Inc.

Affine Formulations Limited

Beacon Pharmaceuticals

Biocon Limited

Boehringer Ingelheim

Bristol-Myers Squibb Company

Cipla

Frontier Biotechnologies

Genentech, Inc.

Gilead Sciences, Inc

IPCA Laboratories

Janssen Pharmaceuticals, Inc.

Julphar Bangladesh

Merck & Co

MSD

Mylan Pharmaceuticals Inc.

Natco Pharma

Roche Holding AG

Shionogi

Theratechnologies Inc.

ViiV Healthcare

GSK

Pfizer

Johnson & Johnson

Teva Pharmaceuticals

Abbott

HIV Therapy Drug Segment by Type

Hiv Integrated Enzyme Chain Transfer Inhibitor

Multi-Type Combined Drugs

Non-Nucleoside Reverse Transcription Enzyme Inhibitors

Nucleoside Reverse Transcription Enzyme Inhibitors

HIV Therapy Drug Segment by Application

Hospital

Clinic

Pharmacy

HIV Therapy Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global HIV Therapy Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions HIV Therapy Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify HIV Therapy Drug significant trends, drivers, influence factors in global and regions.

6. To analyze HIV Therapy Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Therapy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV Therapy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Therapy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the HIV Therapy Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global HIV Therapy Drug industry.

Chapter 3: Detailed analysis of HIV Therapy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of HIV Therapy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of HIV Therapy Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. HIV Therapy Drug Industry Trends Table 2. HIV Therapy Drug Industry Drivers Table 3. HIV Therapy Drug Industry Opportunities and Challenges Table 4. HIV Therapy Drug Industry Restraints Table 5. Global HIV Therapy Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global HIV Therapy Drug Revenue Share by Company (2021-2026) Table 7. Global HIV Therapy Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global HIV Therapy Drug Sales Volume Share by Company (2021-2026) Table 9. Global HIV Therapy Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global HIV Therapy Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global HIV Therapy Drug Key Company Manufacturing Base & Headquarters Table 12. Global HIV Therapy Drug Company, Product Type & Application Table 13. Global HIV Therapy Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global HIV Therapy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Hiv Integrated Enzyme Chain Transfer Inhibitor Table 18. Significant Companies of Multi-Type Combined Drugs Table 19. Significant Companies of Non-Nucleoside Reverse Transcription Enzyme Inhibitors Table 20. Significant Companies of Nucleoside Reverse Transcription Enzyme Inhibitors Table 21. Global HIV Therapy Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global HIV Therapy Drug Sales Volume by Type (2021-2026) & (K Units) Table 23. Global HIV Therapy Drug Sales Volume by Type (2027-2032) & (K Units) Table 24. Global HIV Therapy Drug Sales Volume Share by Type (2021-2026) Table 25. Global HIV Therapy Drug Sales Volume Share by Type (2027-2032) Table 26. Global HIV Therapy Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global HIV Therapy Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global HIV Therapy Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global HIV Therapy Drug Sales Value Share by Type (2021-2026) Table 30. Global HIV Therapy Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Pharmacy Table 34. Global HIV Therapy Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global HIV Therapy Drug Sales Volume by Application (2021-2026) & (K Units) Table 36. Global HIV Therapy Drug Sales Volume by Application (2027-2032) & (K Units) Table 37. Global HIV Therapy Drug Sales Volume Share by Application (2021-2026) Table 38. Global HIV Therapy Drug Sales Volume Share by Application (2027-2032) Table 39. Global HIV Therapy Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global HIV Therapy Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global HIV Therapy Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global HIV Therapy Drug Sales Value Share by Application (2021-2026) Table 43. Global HIV Therapy Drug Sales Value Share by Application (2027-2032) Table 44. Global HIV Therapy Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global HIV Therapy Drug Sales by Region (2021-2026) & (K Units) Table 46. Global HIV Therapy Drug Sales Market Share by Region (2021-2026) Table 47. Global HIV Therapy Drug Sales by Region (2027-2032) & (K Units) Table 48. Global HIV Therapy Drug Sales Market Share by Region (2027-2032) Table 49. Global HIV Therapy Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global HIV Therapy Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global HIV Therapy Drug Sales Value Share by Region (2021-2026) Table 52. Global HIV Therapy Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global HIV Therapy Drug Sales Value Share by Region (2027-2032) Table 54. Global HIV Therapy Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global HIV Therapy Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global HIV Therapy Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global HIV Therapy Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global HIV Therapy Drug Sales by Country (2021-2026) & (K Units) Table 59. Global HIV Therapy Drug Sales Market Share by Country (2021-2026) Table 60. Global HIV Therapy Drug Sales by Country (2027-2032) & (K Units) Table 61. Global HIV Therapy Drug Sales Market Share by Country (2027-2032) Table 62. Global HIV Therapy Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global HIV Therapy Drug Sales Value Market Share by Country (2021-2026) Table 64. Global HIV Therapy Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global HIV Therapy Drug Sales Value Market Share by Country (2027-2032) Table 66. AbbVie Inc. Company Information Table 67. AbbVie Inc. Business Overview Table 68. AbbVie Inc. HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. AbbVie Inc. HIV Therapy Drug Product Portfolio Table 70. AbbVie Inc. Recent Development Table 71. Affine Formulations Limited Company Information Table 72. Affine Formulations Limited Business Overview Table 73. Affine Formulations Limited HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Affine Formulations Limited HIV Therapy Drug Product Portfolio Table 75. Affine Formulations Limited Recent Development Table 76. Beacon Pharmaceuticals Company Information Table 77. Beacon Pharmaceuticals Business Overview Table 78. Beacon Pharmaceuticals HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Beacon Pharmaceuticals HIV Therapy Drug Product Portfolio Table 80. Beacon Pharmaceuticals Recent Development Table 81. Biocon Limited Company Information Table 82. Biocon Limited Business Overview Table 83. Biocon Limited HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Biocon Limited HIV Therapy Drug Product Portfolio Table 85. Biocon Limited Recent Development Table 86. Boehringer Ingelheim Company Information Table 87. Boehringer Ingelheim Business Overview Table 88. Boehringer Ingelheim HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Boehringer Ingelheim HIV Therapy Drug Product Portfolio Table 90. Boehringer Ingelheim Recent Development Table 91. Bristol-Myers Squibb Company Company Information Table 92. Bristol-Myers Squibb Company Business Overview Table 93. Bristol-Myers Squibb Company HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Bristol-Myers Squibb Company HIV Therapy Drug Product Portfolio Table 95. Bristol-Myers Squibb Company Recent Development Table 96. Cipla Company Information Table 97. Cipla Business Overview Table 98. Cipla HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Cipla HIV Therapy Drug Product Portfolio Table 100. Cipla Recent Development Table 101. Frontier Biotechnologies Company Information Table 102. Frontier Biotechnologies Business Overview Table 103. Frontier Biotechnologies HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Frontier Biotechnologies HIV Therapy Drug Product Portfolio Table 105. Frontier Biotechnologies Recent Development Table 106. Genentech, Inc. Company Information Table 107. Genentech, Inc. Business Overview Table 108. Genentech, Inc. HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Genentech, Inc. HIV Therapy Drug Product Portfolio Table 110. Genentech, Inc. Recent Development Table 111. Gilead Sciences, Inc Company Information Table 112. Gilead Sciences, Inc Business Overview Table 113. Gilead Sciences, Inc HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Gilead Sciences, Inc HIV Therapy Drug Product Portfolio Table 115. Gilead Sciences, Inc Recent Development Table 116. IPCA Laboratories Company Information Table 117. IPCA Laboratories Business Overview Table 118. IPCA Laboratories HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. IPCA Laboratories HIV Therapy Drug Product Portfolio Table 120. IPCA Laboratories Recent Development Table 121. Janssen Pharmaceuticals, Inc. Company Information Table 122. Janssen Pharmaceuticals, Inc. Business Overview Table 123. Janssen Pharmaceuticals, Inc. HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Janssen Pharmaceuticals, Inc. HIV Therapy Drug Product Portfolio Table 125. Janssen Pharmaceuticals, Inc. Recent Development Table 126. Julphar Bangladesh Company Information Table 127. Julphar Bangladesh Business Overview Table 128. Julphar Bangladesh HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Julphar Bangladesh HIV Therapy Drug Product Portfolio Table 130. Julphar Bangladesh Recent Development Table 131. Merck & Co Company Information Table 132. Merck & Co Business Overview Table 133. Merck & Co HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Merck & Co HIV Therapy Drug Product Portfolio Table 135. Merck & Co Recent Development Table 136. MSD Company Information Table 137. MSD Business Overview Table 138. MSD HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. MSD HIV Therapy Drug Product Portfolio Table 140. MSD Recent Development Table 141. Mylan Pharmaceuticals Inc. Company Information Table 142. Mylan Pharmaceuticals Inc. Business Overview Table 143. Mylan Pharmaceuticals Inc. HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Mylan Pharmaceuticals Inc. HIV Therapy Drug Product Portfolio Table 145. Mylan Pharmaceuticals Inc. Recent Development Table 146. Natco Pharma Company Information Table 147. Natco Pharma Business Overview Table 148. Natco Pharma HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Natco Pharma HIV Therapy Drug Product Portfolio Table 150. Natco Pharma Recent Development Table 151. Roche Holding AG Company Information Table 152. Roche Holding AG Business Overview Table 153. Roche Holding AG HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Roche Holding AG HIV Therapy Drug Product Portfolio Table 155. Roche Holding AG Recent Development Table 156. Shionogi Company Information Table 157. Shionogi Business Overview Table 158. Shionogi HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Shionogi HIV Therapy Drug Product Portfolio Table 160. Shionogi Recent Development Table 161. Theratechnologies Inc. Company Information Table 162. Theratechnologies Inc. Business Overview Table 163. Theratechnologies Inc. HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Theratechnologies Inc. HIV Therapy Drug Product Portfolio Table 165. Theratechnologies Inc. Recent Development Table 166. ViiV Healthcare Company Information Table 167. ViiV Healthcare Business Overview Table 168. ViiV Healthcare HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. ViiV Healthcare HIV Therapy Drug Product Portfolio Table 170. ViiV Healthcare Recent Development Table 171. GSK Company Information Table 172. GSK Business Overview Table 173. GSK HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 174. GSK HIV Therapy Drug Product Portfolio Table 175. GSK Recent Development Table 176. Pfizer Company Information Table 177. Pfizer Business Overview Table 178. Pfizer HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 179. Pfizer HIV Therapy Drug Product Portfolio Table 180. Pfizer Recent Development Table 181. Johnson & Johnson Company Information Table 182. Johnson & Johnson Business Overview Table 183. Johnson & Johnson HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 184. Johnson & Johnson HIV Therapy Drug Product Portfolio Table 185. Johnson & Johnson Recent Development Table 186. Teva Pharmaceuticals Company Information Table 187. Teva Pharmaceuticals Business Overview Table 188. Teva Pharmaceuticals HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 189. Teva Pharmaceuticals HIV Therapy Drug Product Portfolio Table 190. Teva Pharmaceuticals Recent Development Table 191. Abbott Company Information Table 192. Abbott Business Overview Table 193. Abbott HIV Therapy Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 194. Abbott HIV Therapy Drug Product Portfolio Table 195. Abbott Recent Development Table 196. Key Raw Materials Table 197. Raw Materials Key Suppliers Table 198. HIV Therapy Drug Distributors List Table 199. HIV Therapy Drug Customers List Table 200. Research Programs/Design for This Report Table 201. Authors List of This Report Table 202. Secondary Sources Table 203. Primary Sources List of Figures Figure 1. HIV Therapy Drug Product Image Figure 2. Global HIV Therapy Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV Therapy Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global HIV Therapy Drug Sales (2021-2032) & (K Units) Figure 5. Global HIV Therapy Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global HIV Therapy Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Hiv Integrated Enzyme Chain Transfer Inhibitor Image Figure 10. Multi-Type Combined Drugs Image Figure 11. Non-Nucleoside Reverse Transcription Enzyme Inhibitors Image Figure 12. Nucleoside Reverse Transcription Enzyme Inhibitors Image Figure 13. Global HIV Therapy Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global HIV Therapy Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global HIV Therapy Drug Sales Volume Share by Type (2021-2032) Figure 16. Global HIV Therapy Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global HIV Therapy Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global HIV Therapy Drug Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Pharmacy Image Figure 22. Global HIV Therapy Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global HIV Therapy Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global HIV Therapy Drug Sales Volume Share by Application (2021-2032) Figure 25. Global HIV Therapy Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global HIV Therapy Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global HIV Therapy Drug Sales Value Share by Application (2021-2032) Figure 28. Global HIV Therapy Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global HIV Therapy Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global HIV Therapy Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global HIV Therapy Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America HIV Therapy Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America HIV Therapy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe HIV Therapy Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe HIV Therapy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific HIV Therapy Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific HIV Therapy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America HIV Therapy Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America HIV Therapy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa HIV Therapy Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa HIV Therapy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt HIV Therapy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. HIV Therapy Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. HIV Therapy Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Hiv Integrated Enzyme Chain Transfer Inhibitor
  • Multi-Type Combined Drugs
  • Non-Nucleoside Reverse Transcription Enzyme Inhibitors
  • Nucleoside Reverse Transcription Enzyme Inhibitors
Applications
  • Hospital
  • Clinic
  • Pharmacy
Companies covered
  • AbbVie Inc.
  • Affine Formulations Limited
  • Beacon Pharmaceuticals
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Cipla
  • Frontier Biotechnologies
  • Genentech, Inc.
  • Gilead Sciences, Inc
  • IPCA Laboratories
  • Janssen Pharmaceuticals, Inc.
  • Julphar Bangladesh
  • Merck & Co
  • MSD
  • Mylan Pharmaceuticals Inc.
  • Natco Pharma
  • Roche Holding AG
  • Shionogi
  • Theratechnologies Inc.
  • ViiV Healthcare
  • GSK
  • Pfizer
  • Johnson & Johnson
  • Teva Pharmaceuticals
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global HIV Therapy Drug Sales Value (2021-2032)
  4. 1.2.2 Global HIV Therapy Drug Sales Volume (2021-2032)
  5. 1.2.3 Global HIV Therapy Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 HIV Therapy Drug Market Dynamics
  1. 2.1 HIV Therapy Drug Industry Trends
  2. 2.2 HIV Therapy Drug Industry Drivers
  3. 2.3 HIV Therapy Drug Industry Opportunities and Challenges
  4. 2.4 HIV Therapy Drug Industry Restraints
3 HIV Therapy Drug Market by Company
  1. 3.1 Global HIV Therapy Drug Company Revenue Ranking in 2025
  2. 3.2 Global HIV Therapy Drug Revenue by Company (2021-2026)
  3. 3.3 Global HIV Therapy Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global HIV Therapy Drug Average Price by Company (2021-2026)
  5. 3.5 Global HIV Therapy Drug Company Ranking (2024-2026)
  6. 3.6 Global HIV Therapy Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global HIV Therapy Drug Company Product Type and Application
  8. 3.8 Global HIV Therapy Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global HIV Therapy Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 HIV Therapy Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 HIV Therapy Drug Market by Type
  1. 4.1 HIV Therapy Drug Type Introduction
  2. 4.1.1 Hiv Integrated Enzyme Chain Transfer Inhibitor
  3. 4.1.2 Multi-Type Combined Drugs
  4. 4.1.3 Non-Nucleoside Reverse Transcription Enzyme Inhibitors
  5. 4.1.4 Nucleoside Reverse Transcription Enzyme Inhibitors
  6. 4.2 Global HIV Therapy Drug Sales Volume by Type
  7. 4.2.1 Global HIV Therapy Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global HIV Therapy Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global HIV Therapy Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global HIV Therapy Drug Sales Value by Type
  11. 4.3.1 Global HIV Therapy Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global HIV Therapy Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global HIV Therapy Drug Sales Value Share by Type (2021-2032)
5 HIV Therapy Drug Market by Application
  1. 5.1 HIV Therapy Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Pharmacy
  5. 5.2 Global HIV Therapy Drug Sales Volume by Application
  6. 5.2.1 Global HIV Therapy Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global HIV Therapy Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global HIV Therapy Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global HIV Therapy Drug Sales Value by Application
  10. 5.3.1 Global HIV Therapy Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global HIV Therapy Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global HIV Therapy Drug Sales Value Share by Application (2021-2032)
6 HIV Therapy Drug Regional Sales and Value Analysis
  1. 6.1 Global HIV Therapy Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HIV Therapy Drug Sales by Region (2021-2032)
  3. 6.2.1 Global HIV Therapy Drug Sales by Region: 2021-2026
  4. 6.2.2 Global HIV Therapy Drug Sales by Region (2027-2032)
  5. 6.3 Global HIV Therapy Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global HIV Therapy Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global HIV Therapy Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global HIV Therapy Drug Sales Value by Region (2027-2032)
  9. 6.5 Global HIV Therapy Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America HIV Therapy Drug Sales Value (2021-2032)
  12. 6.6.2 North America HIV Therapy Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe HIV Therapy Drug Sales Value (2021-2032)
  15. 6.7.2 Europe HIV Therapy Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific HIV Therapy Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific HIV Therapy Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America HIV Therapy Drug Sales Value (2021-2032)
  21. 6.9.2 South America HIV Therapy Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa HIV Therapy Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa HIV Therapy Drug Sales Value Share by Country, 2025 VS 2032
7 HIV Therapy Drug Country-level Sales and Value Analysis
  1. 7.1 Global HIV Therapy Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global HIV Therapy Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global HIV Therapy Drug Sales by Country (2021-2032)
  4. 7.3.1 Global HIV Therapy Drug Sales by Country (2021-2026)
  5. 7.3.2 Global HIV Therapy Drug Sales by Country (2027-2032)
  6. 7.4 Global HIV Therapy Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global HIV Therapy Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global HIV Therapy Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt HIV Therapy Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt HIV Therapy Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt HIV Therapy Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie Inc.
  2. 8.1.1 AbbVie Inc. Company Information
  3. 8.1.2 AbbVie Inc. Business Overview
  4. 8.1.3 AbbVie Inc. HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Inc. HIV Therapy Drug Product Portfolio
  6. 8.1.5 AbbVie Inc. Recent Developments
  7. 8.2 Affine Formulations Limited
  8. 8.2.1 Affine Formulations Limited Company Information
  9. 8.2.2 Affine Formulations Limited Business Overview
  10. 8.2.3 Affine Formulations Limited HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Affine Formulations Limited HIV Therapy Drug Product Portfolio
  12. 8.2.5 Affine Formulations Limited Recent Developments
  13. 8.3 Beacon Pharmaceuticals
  14. 8.3.1 Beacon Pharmaceuticals Company Information
  15. 8.3.2 Beacon Pharmaceuticals Business Overview
  16. 8.3.3 Beacon Pharmaceuticals HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Beacon Pharmaceuticals HIV Therapy Drug Product Portfolio
  18. 8.3.5 Beacon Pharmaceuticals Recent Developments
  19. 8.4 Biocon Limited
  20. 8.4.1 Biocon Limited Company Information
  21. 8.4.2 Biocon Limited Business Overview
  22. 8.4.3 Biocon Limited HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Biocon Limited HIV Therapy Drug Product Portfolio
  24. 8.4.5 Biocon Limited Recent Developments
  25. 8.5 Boehringer Ingelheim
  26. 8.5.1 Boehringer Ingelheim Company Information
  27. 8.5.2 Boehringer Ingelheim Business Overview
  28. 8.5.3 Boehringer Ingelheim HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Boehringer Ingelheim HIV Therapy Drug Product Portfolio
  30. 8.5.5 Boehringer Ingelheim Recent Developments
  31. 8.6 Bristol-Myers Squibb Company
  32. 8.6.1 Bristol-Myers Squibb Company Company Information
  33. 8.6.2 Bristol-Myers Squibb Company Business Overview
  34. 8.6.3 Bristol-Myers Squibb Company HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bristol-Myers Squibb Company HIV Therapy Drug Product Portfolio
  36. 8.6.5 Bristol-Myers Squibb Company Recent Developments
  37. 8.7 Cipla
  38. 8.7.1 Cipla Company Information
  39. 8.7.2 Cipla Business Overview
  40. 8.7.3 Cipla HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Cipla HIV Therapy Drug Product Portfolio
  42. 8.7.5 Cipla Recent Developments
  43. 8.8 Frontier Biotechnologies
  44. 8.8.1 Frontier Biotechnologies Company Information
  45. 8.8.2 Frontier Biotechnologies Business Overview
  46. 8.8.3 Frontier Biotechnologies HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Frontier Biotechnologies HIV Therapy Drug Product Portfolio
  48. 8.8.5 Frontier Biotechnologies Recent Developments
  49. 8.9 Genentech, Inc.
  50. 8.9.1 Genentech, Inc. Company Information
  51. 8.9.2 Genentech, Inc. Business Overview
  52. 8.9.3 Genentech, Inc. HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Genentech, Inc. HIV Therapy Drug Product Portfolio
  54. 8.9.5 Genentech, Inc. Recent Developments
  55. 8.10 Gilead Sciences, Inc
  56. 8.10.1 Gilead Sciences, Inc Company Information
  57. 8.10.2 Gilead Sciences, Inc Business Overview
  58. 8.10.3 Gilead Sciences, Inc HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Gilead Sciences, Inc HIV Therapy Drug Product Portfolio
  60. 8.10.5 Gilead Sciences, Inc Recent Developments
  61. 8.11 IPCA Laboratories
  62. 8.11.1 IPCA Laboratories Company Information
  63. 8.11.2 IPCA Laboratories Business Overview
  64. 8.11.3 IPCA Laboratories HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 IPCA Laboratories HIV Therapy Drug Product Portfolio
  66. 8.11.5 IPCA Laboratories Recent Developments
  67. 8.12 Janssen Pharmaceuticals, Inc.
  68. 8.12.1 Janssen Pharmaceuticals, Inc. Company Information
  69. 8.12.2 Janssen Pharmaceuticals, Inc. Business Overview
  70. 8.12.3 Janssen Pharmaceuticals, Inc. HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Janssen Pharmaceuticals, Inc. HIV Therapy Drug Product Portfolio
  72. 8.12.5 Janssen Pharmaceuticals, Inc. Recent Developments
  73. 8.13 Julphar Bangladesh
  74. 8.13.1 Julphar Bangladesh Company Information
  75. 8.13.2 Julphar Bangladesh Business Overview
  76. 8.13.3 Julphar Bangladesh HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Julphar Bangladesh HIV Therapy Drug Product Portfolio
  78. 8.13.5 Julphar Bangladesh Recent Developments
  79. 8.14 Merck & Co
  80. 8.14.1 Merck & Co Company Information
  81. 8.14.2 Merck & Co Business Overview
  82. 8.14.3 Merck & Co HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Merck & Co HIV Therapy Drug Product Portfolio
  84. 8.14.5 Merck & Co Recent Developments
  85. 8.15 MSD
  86. 8.15.1 MSD Company Information
  87. 8.15.2 MSD Business Overview
  88. 8.15.3 MSD HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 MSD HIV Therapy Drug Product Portfolio
  90. 8.15.5 MSD Recent Developments
  91. 8.16 Mylan Pharmaceuticals Inc.
  92. 8.16.1 Mylan Pharmaceuticals Inc. Company Information
  93. 8.16.2 Mylan Pharmaceuticals Inc. Business Overview
  94. 8.16.3 Mylan Pharmaceuticals Inc. HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Mylan Pharmaceuticals Inc. HIV Therapy Drug Product Portfolio
  96. 8.16.5 Mylan Pharmaceuticals Inc. Recent Developments
  97. 8.17 Natco Pharma
  98. 8.17.1 Natco Pharma Company Information
  99. 8.17.2 Natco Pharma Business Overview
  100. 8.17.3 Natco Pharma HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Natco Pharma HIV Therapy Drug Product Portfolio
  102. 8.17.5 Natco Pharma Recent Developments
  103. 8.18 Roche Holding AG
  104. 8.18.1 Roche Holding AG Company Information
  105. 8.18.2 Roche Holding AG Business Overview
  106. 8.18.3 Roche Holding AG HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Roche Holding AG HIV Therapy Drug Product Portfolio
  108. 8.18.5 Roche Holding AG Recent Developments
  109. 8.19 Shionogi
  110. 8.19.1 Shionogi Company Information
  111. 8.19.2 Shionogi Business Overview
  112. 8.19.3 Shionogi HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Shionogi HIV Therapy Drug Product Portfolio
  114. 8.19.5 Shionogi Recent Developments
  115. 8.20 Theratechnologies Inc.
  116. 8.20.1 Theratechnologies Inc. Company Information
  117. 8.20.2 Theratechnologies Inc. Business Overview
  118. 8.20.3 Theratechnologies Inc. HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Theratechnologies Inc. HIV Therapy Drug Product Portfolio
  120. 8.20.5 Theratechnologies Inc. Recent Developments
  121. 8.21 ViiV Healthcare
  122. 8.21.1 ViiV Healthcare Company Information
  123. 8.21.2 ViiV Healthcare Business Overview
  124. 8.21.3 ViiV Healthcare HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 ViiV Healthcare HIV Therapy Drug Product Portfolio
  126. 8.21.5 ViiV Healthcare Recent Developments
  127. 8.22 GSK
  128. 8.22.1 GSK Company Information
  129. 8.22.2 GSK Business Overview
  130. 8.22.3 GSK HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 GSK HIV Therapy Drug Product Portfolio
  132. 8.22.5 GSK Recent Developments
  133. 8.23 Pfizer
  134. 8.23.1 Pfizer Company Information
  135. 8.23.2 Pfizer Business Overview
  136. 8.23.3 Pfizer HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Pfizer HIV Therapy Drug Product Portfolio
  138. 8.23.5 Pfizer Recent Developments
  139. 8.24 Johnson & Johnson
  140. 8.24.1 Johnson & Johnson Company Information
  141. 8.24.2 Johnson & Johnson Business Overview
  142. 8.24.3 Johnson & Johnson HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Johnson & Johnson HIV Therapy Drug Product Portfolio
  144. 8.24.5 Johnson & Johnson Recent Developments
  145. 8.25 Teva Pharmaceuticals
  146. 8.25.1 Teva Pharmaceuticals Company Information
  147. 8.25.2 Teva Pharmaceuticals Business Overview
  148. 8.25.3 Teva Pharmaceuticals HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Teva Pharmaceuticals HIV Therapy Drug Product Portfolio
  150. 8.25.5 Teva Pharmaceuticals Recent Developments
  151. 8.26 Abbott
  152. 8.26.1 Abbott Company Information
  153. 8.26.2 Abbott Business Overview
  154. 8.26.3 Abbott HIV Therapy Drug Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 Abbott HIV Therapy Drug Product Portfolio
  156. 8.26.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 HIV Therapy Drug Value Chain Analysis
  2. 9.1.1 HIV Therapy Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 HIV Therapy Drug Sales Mode & Process
  6. 9.2 HIV Therapy Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 HIV Therapy Drug Distributors
  9. 9.2.3 HIV Therapy Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst